	US 12,071,465 B2
	Methods of making and using extracellular domain-based chimeric proteins
Taylor Schreiber, Austin, TX (US); George Fromm, Austin, TX (US); and Suresh De Silva, Austin, TX (US)
Assigned to Shattuck Labs, Inc., Austin, TX (US)
Filed by Shattuck Labs, Inc., Austin, TX (US)
Filed on Apr. 11, 2022, as Appl. No. 17/717,740.
Application 17/717,740 is a continuation of application No. 16/484,852, granted, now 11,332,509, previously published as PCT/US2018/020040, filed on Feb. 27, 2018.
Claims priority of provisional application 62/464,002, filed on Feb. 27, 2017.
Prior Publication US 2022/0315637 A1, Oct. 6, 2022
Int. Cl. A61K 38/17 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01); C07K 14/525 (2006.01); C07K 14/705 (2006.01)

CPC C07K 14/705 (2013.01) [A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61P 35/00 (2018.01); C07K 14/525 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

20 Claims

1. A method of treating a tumor that expresses CSF1, CEACAM1, and/or galectin-9, comprising administering to a subject in need thereof:

(i) a first chimeric protein of a general structure of:

N terminus-(a)-(b)-(c)-C terminus,

wherein:

(a) is a first domain comprising an extracellular domain of TIM3,

(b) is a linker comprising at least one cysteine residue capable of forming a disulfide bond, and

and

(ii) a second chimeric protein of a general structure of:

N terminus-(a)-(b)-(c)-C terminus,

wherein:

(a) is a first domain comprising an extracellular domain of CSFIR,

(b) is a linker comprising at least one cysteine residue capable of forming a disulfide bond, and